BMY logo

Bristol Myers Squibb

BMY · What the business does, what can go wrong, and how options sellers approach it

What it does

Bristol-Myers Squibb is a large pharmaceutical company that discovers, develops and sells prescription medicines. Its work spans cancer, blood disorders, immune diseases and cardiovascular conditions. Immuno-oncology, which uses the body's immune system to fight tumors, has been a major area of focus.

The company sells mainly to wholesalers, hospitals, pharmacies and health systems, and the United States is its largest market.

How it makes money

BMY earns revenue by selling branded drugs that are protected by patents. While a drug has exclusivity, the company can set a price that reflects its value and the cost of developing it. It also receives royalties and collaboration income from some partnerships.

Why investors own it

Investors often look at BMY for its established portfolio of branded medicines, its cash generation and its history of paying a dividend. Pharma stocks are also sometimes viewed as defensive, because demand for medicine tends to hold up when the economy slows. Some investors like the pipeline of new drugs as a potential source of future growth.

What can go wrong

  • Patent expirations: When exclusivity ends, generics or biosimilars can take sales quickly. This is the central risk for the sector.
  • Pipeline setbacks: Clinical trials can fail, and regulators can delay or reject approvals.
  • Pricing pressure: US drug pricing policy, insurer negotiation and government programs can limit what the company earns.
  • Competition: Rival drugs in cancer and immunology can erode market position.
  • Concentration: A few products can make up a large share of sales, so trouble with one matters.
  • Dividend: Payouts are decided by the board and are not guaranteed.

What to watch

  • Patent expiration dates for key medicines
  • Clinical trial readouts and regulatory decisions
  • Sales trends of core and newer products
  • US drug pricing and reimbursement policy changes
  • Business development, such as licensing deals and acquisitions
  • Free cash flow and dividend coverage

Options income angle

Options on BMY are typically liquid, especially near-term contracts. Implied volatility tends to rise around earnings, trial results, regulatory decisions and drug pricing news. Outside those events, implied volatility tends to be lower.

One caution for premium sellers: a surprise trial failure or policy headline can gap the shares sharply, so a short put can leave you owning stock well below the strike.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 11, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Bristol Myers Squibb reported revenue that was essentially unchanged in 2025, as growth in newer products and Eliquis offset generic competition on older cancer drugs. The filing stresses that government price-setting and patent expirations are cutting into the older portfolio, and that royalty income of about $2.7 billion before tax is starting to roll off. Management points to the pipeline and cost savings to fill the gap.

How the business did

  • Total revenues were $48,194 million versus $48,300 million in 2024. The Growth Portfolio (newer products) reached $26,409 million, up 17%. The Legacy Portfolio (older products) fell to $21,785 million, down 15%.
  • Eliquis revenue rose 8% to $14,443 million. Revlimid U.S. revenue fell 49% and Sprycel U.S. revenue fell 70% on generic competition. Breyanzi (up 82%), Camzyos (up 77%) and Reblozyl (up 31%) were standout growth products.
  • Rebates and discounts took a bigger bite. The gross-to-net adjustments percentage, which measures how much of list-price sales is given back, rose to 47% from 44%, mainly because of the Medicare Part D redesign and a higher share of government-channel sales.
  • GAAP diluted earnings per share were $3.46 versus a loss of $(4.41). The swing came mainly from lower acquired in-process R&D charges (upfront payments for early-stage drug rights), lower amortization and cost savings. Non-GAAP EPS, which excludes items management calls unusual, was $6.15 versus $1.15.
  • Operating cash flow was $14.2 billion and dividends were $5.0 billion. There were no share repurchases. The company redeemed $8.7 billion of debt and ended with a net debt position of $(34,043) million.

Risks specific to this company

  • Government price-setting: Under the Inflation Reduction Act, a Medicare "maximum fair price" for Eliquis took effect January 1, 2026, and one for Pomalyst follows January 1, 2027. Orencia was selected in January 2026 for prices starting in 2028.
  • Product concentration: The filing says a majority of revenue and earnings come from several key products: Eliquis, Opdivo, Opdivo Qvantig, Orencia, Reblozyl and Yervoy. Any one of them losing exclusivity or facing new problems would hit results.
  • Patent challenges: Generic Eliquis is already sold in some European countries, including the UK and Finland, before patents expire. U.S. generic lenalidomide licenses stopped being volume-limited as of January 31, 2026, and generic pomalidomide is expected in the U.S. in March 2026.
  • Royalties ending: Keytruda and Tecentriq royalties are expected to end December 31, 2026, and the diabetes royalties ended December 31, 2025.
  • Debt: Borrowing for the Mirati, Karuna and RayzeBio deals limits financial flexibility. Standard & Poor's earlier cut the long-term rating from A+ to A.
  • Pipeline setbacks: The 2025 trial misses included Camzyos in non-obstructive HCM and Cobenfy as an add-on in schizophrenia. The milvexian ACS trial was stopped. The filing also lists $19.1 billion of other intangible assets that could be written down if development fails.

What management is watching

  • Management expects continued generic erosion in 2026, mainly from Revlimid and Pomalyst in the U.S.
  • A productivity initiative is expected to deliver approximately $2.0 billion in cost savings by the end of 2027. Capital spending is expected to be approximately $1.3 billion in 2026, with more U.S. manufacturing planned.
  • Upcoming catalysts include topline data in 2026 from the Librexia AF and Librexia STROKE trials, an FDA decision date of March 6, 2026 for Sotyktu in psoriatic arthritis, and April 8, 2026 for Opdivo in Hodgkin lymphoma.
  • Pipeline bets named include the BioNTech bispecific antibody pumitamig, radiopharmaceuticals, CAR-T cell therapies and Cobenfy in Alzheimer's-related conditions.
  • Management points investors to non-GAAP earnings and to international revenue excluding foreign exchange.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Bristol Myers Squibb reported third-quarter total revenues of $13,069 million, up 7%, as newer medicines and Eliquis grew while older drugs lost sales to generics. Diluted earnings per share (EPS) under standard accounting (GAAP) were $1.05 versus $1.08 a year earlier. Non-GAAP EPS, which strips out items management considers unusual, was $1.35 versus $1.63. The company blamed higher one-time charges for acquired research rights and the end of diabetes royalty income.

How the business did

  • Revenue: Nine-month revenues were $37,532 million versus $35,692 million, up 5%. The Growth Portfolio (newer products) reached $7,662 million for the quarter, up 12%. Breyanzi rose 46%, Camzyos 42% and Reblozyl 22%. Opdivo fell 6% as U.S. demand shifted to Opdivo Qvantig, whose revenue was $334 million.
  • Eliquis and generics: Eliquis revenue was $4,690 million, up 25%. The company cut its U.S. list price in 2026, which lowered rebates and raised the average net price it realized. Revlimid ($303 million) fell 47% and Pomalyst/Imnovid ($130 million) fell 81% on generic competition.
  • Costs and profit: Acquired IPRD charges (upfront payments for licensing or buying drugs still in development) were $1,558 million versus $633 million. They included $775 million for Hengrui and $500 million for BioNTech. Cost of products sold rose by $711 million, mainly from Eliquis alliance profit sharing, plus a one-time $140 million contract termination charge. Amortization of acquired intangibles fell to $458 million from $831 million because the Pomalyst product right was fully amortized in the fourth quarter of 2025. Nine-month GAAP EPS was $3.98 versus $2.93.
  • Cash and capital return: Nine-month operating cash flow was $8,678 million versus $12,182 million. The company cited lower customer cash collections from generic erosion and the Eliquis list price cut. It paid dividends of $3.9 billion and repaid $1.7 billion of debt. Net debt was $29,918 million, versus $34,043 million at December 31, 2025.

What management is watching

  • Cost savings and spending: The strategic productivity initiative targets annual savings of approximately $2.0 billion by the end of 2027. Spending includes the Hengrui licenses for 13 early stage assets and plans for a Houston manufacturing campus and an Indiana radiopharmaceutical facility.
  • Pricing and patents: Under the IRA, Medicare "maximum fair prices" applied to Eliquis from January 1, 2026 and apply to Pomalyst from January 1, 2027. Orencia was selected for government-set prices beginning in 2028. Tariff relief under a U.S. government agreement runs until January 2029. Eliquis composition patents in the EU expire in November 2026, and in October 2026 the company and Pfizer began a U.S. patent infringement action over Eliquis.
  • Pipeline: The FDA set a PDUFA decision date (its target date for a ruling) of May 13, 2027 for mezigdomide and March 11, 2027 for a Reblozyl expansion. Admilparant met its main goal in a Phase III trial in IPF at the 60 mg dose.
  • Measures to watch: Management points investors to non-GAAP earnings and to revenue growth excluding foreign exchange effects.

Follow BMY in Kortex

The Kortex app shows BMY's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.